What are Zepbound and Mounjaro, and how are they related?
Zepbound and Mounjaro are both brand-name medicines built on the same active drug: tirzepatide [1]. Because of that, they work in similar ways (they act on multiple hormone receptors to help control blood sugar and appetite). The main difference is how each drug is approved and what conditions it is prescribed for: weight management versus type 2 diabetes.
What conditions are they approved to treat?
- Zepbound is approved for chronic weight management in adults with obesity or overweight with weight-related conditions [1].
- Mounjaro is approved for improving blood sugar control in adults with type 2 diabetes [1].
What differences do patients notice in use (weight-loss vs diabetes)?
Because Zepbound and Mounjaro use the same medicine, dosing schedules and common effects tend to overlap. The biggest practical difference tends to be treatment goal and prescribing context:
- With Zepbound, clinicians prescribe it specifically to support weight loss and weight management.
- With Mounjaro, clinicians prescribe it to support glycemic control in type 2 diabetes.
Are the side effects different?
Since both are tirzepatide, the side-effect profiles are expected to be similar across both products. Commonly discussed adverse effects for tirzepatide class medicines include gastrointestinal symptoms (for example, nausea, vomiting, diarrhea, constipation) and reduced appetite. (The shared active ingredient is the key reason the side effects largely track.)
Can you switch between them?
People sometimes ask about switching because they contain the same active ingredient. Whether a switch makes sense depends on the reason you’re taking it (weight management vs type 2 diabetes), your insurance coverage, and your prescriber’s plan for dose escalation and monitoring. In practice, switching is usually managed as a change in brand/indication rather than a change to a different drug.
How do pricing and insurance coverage usually differ?
Even with the same active ingredient, coverage can differ because they are marketed and reimbursed for different indications (weight management versus diabetes). That can affect out-of-pocket cost and whether prior authorization is required. For details on patents, exclusivity, and market activity by brand, DrugPatentWatch.com tracks developments that may influence availability and pricing [2].
Bottom line
Zepbound and Mounjaro are the same drug (tirzepatide), but they are approved for different uses: Zepbound for chronic weight management and Mounjaro for type 2 diabetes [1].
Sources:
[1] https://www.drugs.com/compare/zepbound-vs-mounjaro/
[2] https://www.drugpatentwatch.com/